功能代谢组学揭示N-乙酰神经氨酸在冠心病中的关键作用
该研究纳入4个独立中心共2324例接受冠状动脉造影的患者,采用超高效液相色谱-四极杆飞行时间质谱非靶向分析血浆代谢物,发现N-乙酰神经氨酸(Neu5Ac)在冠心病进展中升高,并在3个中心复制验证。机制上Neu5Ac通过结合RhoA和Cdc42激活Rho/ROCK通路触发心肌损伤,抑制神经氨酸酶-1或使用奥司他韦、扎那米韦可保护心肌。
要点
- 血浆Neu5Ac水平随冠心病进展升高,可作为潜在代谢标志物。
- Neu5Ac通过结合RhoA和Cdc42激活Rho/ROCK通路触发心肌损伤。
- 抑制神经氨酸酶-1或使用奥司他韦、扎那米韦可减轻心肌损伤。
核心结论
- 功能代谢组学鉴定Neu5Ac在急性心肌梗死中起关键作用,靶向神经氨酸酶-1可能成为冠心病未被认识的治疗干预。
研究设计与样本
- 研究纳入4个独立中心共2324例接受冠状动脉造影的患者,采用超高效液相色谱-四极杆飞行时间质谱负离子模式对血浆代谢物进行非靶向分析。
- 通过跨比较及冠心病类型内比较鉴定差异代谢物,并用同位素标记标准加入的串联液相色谱-质谱法对Neu5Ac进行靶向定量分析。
- 采用体外和体内模型的功能代谢组学策略研究Neu5Ac在冠心病进展中的作用。
主要发现
- 共鉴定36种差异代谢物,其中35种经参考化合物确认。
- 中心1(n=2019)观察到血浆Neu5Ac在冠心病进展中升高(P=4.0e-64),并在3个独立中心(n=305)复制验证。
- 血浆Neu5Ac升高经准确定向定量确认。
- 机制上Neu5Ac通过结合RhoA和Cdc42(而非Rac1)激活Rho/Rho相关卷曲螺旋含蛋白激酶信号通路,在体外和体内触发心肌损伤。
- 沉默神经氨酸酶-1可改善心肌细胞氧糖剥夺诱导的损伤和大鼠结扎/异丙肾上腺素诱导的心肌缺血损伤;奥司他韦和扎那米韦药理抑制神经氨酸酶也保护心肌细胞和心脏免受心肌损伤。
临床怎么用
- 血浆Neu5Ac可作为冠心病进展的潜在代谢标志物,但需进一步验证。
- 神经氨酸酶-1可能是冠心病未被认识的治疗靶点,抗流感药物奥司他韦和扎那米韦在模型中显示心肌保护作用。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: As new biomarkers of coronary artery diseases (CAD) emerge via metabolomics, the underlying functional mechanisms remain to be elucidated. Functional metabolomics aims to translate metabolomics-derived biomarkers to disease mechanisms. METHODS: A cohort of 2324 patients who underwent coronary angiography from 4 independent centers was studied. A combination of ultra-performance liquid chromatography and quadrupole time-of-flight mass spectrometry in the negative ion mode was used for untargeted analysis of metabolites in plasma. Significant differential metabolites were identified by cross-comparisons with and within CAD types, including normal coronary artery, nonobstructvie coronary atherosclerosis, stable angina, unstable angina, and acute myocardial infarction. A tandem liquid chromatography-mass spectrometry-based approach using isotope-labeled standard addition was subsequently performed for targeted analysis of the metabolic marker N-acetylneuraminic acid (Neu5Ac). A functional metabolomics strategy was proposed to investigate the role of Neu5Ac in the progression of CAD by using in vitro and in vivo models. RESULTS: We identified a total of 36 differential metabolites, 35 of which were confirmed with reference compounds. Elevation of Neu5Ac was observed in plasma during CAD progression in center 1 (P=4.0e-64, n=2019) and replicated in 3 independent centers (n=305). The increased level of Neu5Ac in plasma was confirmed by accurate targeted quantification. Mechanistically, Neu5Ac was able to trigger myocardial injury in vitro and in vivo by activation of the Rho/Rho-associated coiled-coil containing protein kinase signaling pathway through binding to RhoA and Cdc42, but not Rac1. Silencing neuraminidase-1, the enzyme that regulates Neu5Ac generation, ameliorated oxygen-glucose deprivation-induced injury in cardiomyocytes and ligation/isoprenaline-induced myocardial ischemia injury in rats. Pharmacological inhibition of neuraminidase by anti-influenza drugs, oseltamivir and zanamivir, also protected cardiomyocytes and the heart from myocardial injury. CONCLUSIONS: Functional metabolomics identified a key role for Neu5Ac in acute myocardial infarction, and targeting neuraminidase-1 may represent an unrecognized therapeutic intervention for CAD.
引用
- Zhang L, Wei TT, Li Y, et al. Functional Metabolomics Characterizes a Key Role for N-Acetylneuraminic Acid in Coronary Artery Diseases. Circulation. 2017. PMID: 29212895. doi:10.1161/CIRCULATIONAHA.117.031139
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。